

CASE REPORT**A case of Lawrence Syndrome “acquired generalized lipodystrophy” with type 1 diabetes mellitus in 7 years boy of Bahawalpur**

SUMERA AKRAM

DHQ Hospital, Zhob

Correspondence to Dr. Sumera Akram, Email: akawan79@gmail.com

SUMMARY

Lipodystrophy syndromes are rare disorders characterized by either generalized or partial lack of adipose tissue. They are congenital or acquired. These syndromes are associated with various metabolic and hormonal disorders leading to severe comorbidities including hypertriglyceridemia, diabetes mellitus, acanthosis nigricans, xanthomas, polycystic ovarian syndrome (POS) and non-alcoholic fatty liver disease.

Keywords: Lawrence syndrome, lipodystrophy, diabetes mellitus

INTRODUCTION

Lipodystrophy syndromes consist of rare disorders characterized by either partial or generalized lack of adipose tissue, called partial or generalized lipodystrophy without nutritional deprivation¹. Lipodystrophy is either congenital or acquired². These syndromes are associated with various metabolic and hormonal disorders which lead to severe comorbidities including hypertriglyceridemia, diabetes mellitus, acanthosis nigricans, xanthomas, polycystic ovarian syndrome (POS) and nonalcoholic fatty liver disease^{1,3}. The comorbidities are related to extent of fat loss, gender, age etc. Main causes of mortality in these cases are cardiomyopathy, cardiac failure, renal and liver failure, myocardial infarction, sepsis etc^{4,5,6}. The syndromes are associated with autoimmune disorders like hemolytic anemia, thyroiditis, common viable immune-deficiency etc⁷.

Majority of complications of these syndromes occur owing to deficiency of adipose (fat) tissue which causes ectopic fat/lipid deposition in muscles, liver or other organs of body leading to insulin resistance which causes hypertriglyceridemia, diabetes

mellitus, hepatic fatty disease etc⁶. These cases are resistance to standard treatment for glycemic control.

CASE REPORT

We present a case of 7 years old boy, resident of Bahawalpur, who presented with hyperphagia, uncontrolled blood sugar level and generalized loss of body fat. He had severe insulin resistance, type 1 diabetes mellitus, raised cholesterol levels, hypertriglyceridemia, deranged liver & renal function tests. On physical examination, he had generalized loss of body fat and hepatosplenomegaly.

His hemoglobin was 12.8mg/dL, total leucocyte count was 7.2×10^3 , platelet count was 214×10^3 , serum bilirubin was 0.9mg/dL, serum ALT (alkaline transaminase) was 241U/L, serum alkaline phosphatase was raised (669 U/L), serum urea was raised (66mg/dL), serum creatinine was raised (1.6mg/dL), serum albumin was reduced i.e., 2.3G/dL. His cholesterol levels and triglyceride levels were markedly raised i.e., 785mg/dL and 3167mg/dL respectively. His blood sugar random (BSR) was 409mg/dL and glycosylated hemoglobin was also raised >9%. His C peptide and anti-tissue transglutaminase (Anti TTG) were normal.

Table 1: Laboratory findings

S/No	Laboratory Test	Normal Range	Patient result
1	Hemoglobin	12 – 18 mg/dL	12.8 mg/dL
2	Total Leucocyte Count	$4 - 11 \times 10^3 / \text{mm}^3$	$7.2 \times 10^3 / \text{mm}^3$
3	Platelets Count	$150 - 400 \times 10^3 / \text{mm}^3$	$214 \times 10^3 / \text{mm}^3$
4	Serum Bilirubin	1 – 17.1 mg/dL	0.9 mg/dL
5	Serum Alanine Transaminase	<40 U/L	241 U/L
6	Serum Alkaline phosphatase	<279 G/dL	669 G/dL
7	Serum Urea	10-50 mg/dL	66 mg/dL
8	Serum Creatinine	0.6-1.1 mg/dL	1.6 mg/dL
9	Serum Albumin	3.8-4.4 G/dL	2.3 G/dL
10	Serum Sodium (Na)	136 -146 mmol/L	135mmol/L
11	Serum Potassium (K)	3.5 -5.1 mmol/L	4.8mmol/L
12	Serum Cholesterol	<200mg/dL	785 mg/dL
13	Serum triglycerides (TG)	<150mg/dL	3167 mg/dL
14	Serum HDL	>35 mg/dL	24 mg/dL
15	Blood Sugar Random	<140mg/dL	409mg/dL
16	Hb1Ac	Below 6.0 %	> 9%
17	C peptide	0.9- 7.1 ng/ml	0.11 ng/ml
18	Anti Tissue Transglutaminase levels	Positive = >18 U/ml	11.41 U/ml

Figure 1: Child with Acquired Generalized Lipodystrophy



He was admitted and put on regular insulin according to sliding scale and oral metformin, but failed to control his raised blood glucose levels. His echocardiography was also done, which was normal. Ultrasound abdomen revealed enlarged liver and spleen. Patient is on regular follow up. Despite regular follow-up and efforts for glycemic control, his blood sugar and serum triglycerides levels are high.

DISCUSSION

Lipodystrophy syndromes are usually categorized into four major types: Congenital generalized lipodystrophy (CGL), familial partial lipodystrophy (FPLD), acquired generalized lipodystrophy (AGL)

and acquired partial lipodystrophy (APL)¹. There are other subtypes mentioned in literature including progeroid disease, autoinflammatory disorders, associated with HIV (Human immunodeficiency virus), lipodystrophy caused by injectable drugs etc⁶. We have presented the first case of acquired generalized lipodystrophy in Pakistan and we will limit our discussion to this particular type of lipodystrophy i.e., Acquired Generalized Lipodystrophy also known as Lawrence Syndrome. It is a rare disorder with less than 100 reported cases⁷. AGL is more frequent in females. Female to male ratio being 3:1. It appears commonly in childhood before adolescence but may appear later in life. There is progressive generalized loss of body fat including soles and palms^{1,6}. AGL is frequently associated with various autoimmune diseases.

Our case of Lawrence syndrome was associated with type 1 diabetes mellitus with features of generalized lipodystrophy, raised serum triglycerides levels, hepatosplenomegaly, raised liver, renal enzymes. Similar case was reported by Kumar R et al⁸. Their case of AGL also had associated type 1 Diabetes Mellitus just like ours. Two similar cases were reported by Perk et al, where AGL cases also had type 1 Diabetes Mellitus⁹. Halpern B et al reported a case of AGL who had associated CVI (common variable immunodeficiency) which is an autoimmune disorder⁷. In CVI (common variable immunodeficiency) body doesn't produce antibodies and patient presents with generalized loss of fat and recurrent infections.

CONCLUSION

Lawrence syndrome (Acquired Generalized lipodystrophy) is a rare disorder. Clinicians should be aware of such syndromes for early detection and timely care and management.

Conflict of interest: Nil

REFERENCES

1. Brown RJ, Chair C, Araujo-Vilar D, Cheung PT, Dunger D, Garg A et al. The diagnosis and management of lipodystrophy syndromes: A multi-society practice guideline. *J Endocrinol and Metabol* 2016; 101(12): 4500-11.
2. Chan JL, Oral EA. Clinical classification and treatment of congenital and acquired lipodystrophy. *Endocr Pract* 2010; 16: 310-23.
3. Akinci B, Sahinoz M, Oral E. Lipodystrophy syndromes: Presentation and treatment. [Updated 2018, April 24]. In: Feingold KR, Anawalt B, Boyce A et al, Editors. *Endotext* [Internet]. South Dartmouth (MA): MDText.com, Inc. : 2000. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK/513130/>.
4. Jackson SN, Howlett TA, McNally PG, O Rahilly S, Trembath RC. Dunningan-Kobberling syndrome: an autosomal dominant form of partial lipodystrophy. *QJM*. 1997; 90(1): 27-36.
5. Garg A. Clinical review : lipodystrophies : genetic and acquired body fat disorders. *J Clin Endocrinol Metab* 2011; 96(11): 3313-3325.
6. Brown RJ, Gorden P. Leptin therapy in patients with lipodystrophy and syndromic insulin resistance. In: Dagogo-Jack S, ed. *Leptin: Regulation and clinical application*. Cham, Switzerland: SpringerInternational Publishing; 2015: 225-236.
7. Halpern B, Nery M, Periera MAA. Case report of acquired generalized lipodystrophy associated with common variable immunodeficiency. *J Clin Endocrinol Metab* 2018; 103(8): 2807-2810.
8. Kumar R, Pilia RK, Bhatia A, Dayal D. Acquired generalized lipodystrophy and type 1 diabetes mellitus in a child: a rare and implacable association. *BMJ Case Report* 2018; 2018: bcr 2018225553. Published online 2018 Aug 3. Doi: 10.1136/bcr-2018-225553.
9. Perk JY, Chong AY, Cochran EK. Type 1 diabetes associated with acquired generalized lipodystrophy with insulin resistance: the effect of long term leptin therapy. *J Clin Endocrinol Metab* 2008; 93: 26-31.